We are pleased to announce the release of a groundbreaking research paper titled "Characterisation of the Cardiovascular Effects of a Meal: QTcF Assessment and Further Insights into the Physiological Effects," authored by Dr. Georg Ferber, Dr. Dilshat Djumanov, Dr. Ulrike Lorch, Dr. Edward Jackson, Dr. Joao Almeida Melo, Mr. James Rickard, and Dr. Jorg Taubel. 

This collaborative effort between Statistik Georg Ferber GmbH, Richmond Pharmacology Ltd, St George’s University of London, King’s College London and Richmond Research Institute delves into the intricate relationship between meals and the QT interval on an electrocardiogram (ECG), particularly when corrected for heart rate using Fridericia's formula (QTcF). 

The study explores the impact of meals on QTcF intervals in the context of integrating Pharmacology studies and Thorough QT (TQT) investigations, providing crucial insights into the potential implications for cardiac health and the risk of arrhythmias. The comprehensive meta-analysis, based on data from nine studies conducted in accordance with ethical standards, sheds light on meal effect QTcF changes, offering valuable perspectives for cardiac safety assessment in clinical trials and drug development. 

The findings also hold promise for more patient-focused practices, contributing to the global fight against antimicrobial resistance (AMR) through the potential reduction of exposure to harmful challenge agents. This research marks a significant step forward in our understanding of the impact of meals on cardiovascular health and aims to accelerate the pace and safety of drug development processes.

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event